Stallergenes Greer Brings National Spotlight to Peanut Allergy Awareness with Palforzia® Segment on Lifetime TV’s “The Balancing Act”
Stallergenes Greer, a global biopharmaceutical company and recognized leader in allergy immunotherapy (AIT), recently announced a major milestone in its public awareness efforts for peanut allergy treatment. The company sponsored a nationally televised segment on Lifetime TV’s popular morning show The Balancing Act®, which aired on Wednesday, July 30, 2025, at 7:30 a.m. ET/PT. The feature showcased Palforzia® [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first and only oral immunotherapy treatment (OIT) approved by the U.S. Food and Drug Administration (FDA) for reducing the incidence of allergic reactions, including anaphylaxis, due to accidental exposure to peanuts in children ages 1 through 17 years.
This initiative marks an important step in Stallergenes Greer’s continued efforts to educate the public, healthcare professionals, and patient communities about both the risks of peanut allergies and the therapeutic solutions available today. The segment featured the compelling real-life story of a family navigating life with a child diagnosed with peanut allergy, offering a deeply personal glimpse into the daily challenges faced by affected families and the transformative impact of FDA-approved immunotherapy.
A Personal Journey to Treatment
At the heart of the broadcast was the emotional and inspiring narrative of a young child with peanut allergy and their family’s journey toward treatment with Palforzia®. Through candid storytelling, the family discussed the constant anxiety, lifestyle adjustments, and social limitations imposed by their child’s severe allergy to peanuts — a common allergen with life-threatening potential.
For many parents, the fear of accidental peanut exposure looms large, whether during school lunches, birthday parties, or even simple family meals. The featured family described how their child’s diagnosis reshaped their everyday routines and the sense of empowerment they felt after beginning treatment with Palforzia®. Their story helped bring to life the potential for oral immunotherapy to alter the trajectory of peanut allergy management, offering hope to thousands of other families living with similar fears.
Leadership Perspective on Raising Awareness
In a statement accompanying the announcement, Tibor Nemes, Executive Vice President and Head of the Americas at Stallergenes Greer, emphasized the importance of national visibility for a condition that often remains misunderstood or underestimated.
“We are proud to see Palforzia® featured on The Balancing Act®, bringing national visibility to peanut allergy and a first-of-its-kind, FDA-approved oral immunotherapy treatment option for children and toddlers,” said Nemes. “This segment is an opportunity to educate patients, caregivers, and healthcare providers about Palforzia®, and to further our commitment as Stallergenes Greer to provide innovative allergen immunotherapy treatments to the allergy community we serve.”
Nemes also noted that the growing prevalence of food allergies — especially peanut allergies — in the pediatric population underscores the need for new, evidence-based interventions that go beyond traditional avoidance strategies. While allergen avoidance remains a foundational aspect of allergy care, treatments like Palforzia® offer a proactive approach aimed at modifying the immune response to the allergen itself.
Clinical Context: The Scope and Severity of Peanut Allergy
Peanut allergy remains one of the most common and dangerous food allergies among children in the United States. Current data indicate that approximately 2% of the U.S. pediatric population lives with a peanut allergy, representing a significant public health concern. According to data cited by Stallergenes Greer, peanut allergies are associated with higher rates of emergency room visits and severe outcomes compared to other food allergies.
What makes peanut allergy especially concerning is its unpredictability. Despite diligent allergen avoidance practices, accidental exposures can and do occur — sometimes with life-threatening consequences. In severe cases, even trace amounts of peanut protein can trigger anaphylaxis, a rapid and potentially fatal allergic reaction.
Studies suggest that children with peanut allergies often experience increased anxiety and social limitations due to the ever-present risk of exposure, Stallergenes which can impact not only their quality of life but also their psychological well-being. This environment of hyper-vigilance places a substantial emotional and logistical burden on both patients and caregivers.
Against this backdrop, the availability of an FDA-approved treatment that reduces the severity of allergic reactions is a breakthrough in pediatric allergy management.
Medical Insight: Expert Commentary on Oral Immunotherapy
The Lifetime TV segment also featured expert insights from Dr. Panida Sriaroon, a board-certified pediatric allergist and immunologist, who provided viewers with a clinical overview of food allergies and the importance of emerging treatment options. Dr. Sriaroon underscored the significance of Palforzia® as the first and only FDA-approved oral immunotherapy for peanut allergy — an achievement that fundamentally shifts how allergists and immunologists approach peanut desensitization.
During her interview, Dr. Sriaroon explained how oral immunotherapy works by gradually exposing patients to controlled, increasing doses of the allergen — in this case, peanut protein — with the goal of building immune tolerance over time. This process reduces the likelihood that a patient will experience a severe reaction if accidentally exposed to peanuts in the future.
By integrating Palforzia® into clinical practice, allergists now have a therapeutic tool that goes beyond symptom management, offering a disease-modifying approach to peanut allergy. The treatment is administered under medical supervision and requires a long-term commitment from both patients and providers, but it represents a significant step forward in providing safer and more active management options for children with peanut allergy.
Regulatory Milestones and Expanded Indications
Palforzia® was originally developed by Aimmune Therapeutics, Inc., which received FDA approval for the product in January 2020. At the time, the therapy was approved for children aged 4 through 17 years who have a confirmed diagnosis of peanut allergy. The treatment was designed specifically to mitigate allergic reactions — including anaphylaxis — resulting from accidental peanut exposure.
Since then, the landscape for Palforzia® has evolved. In 2024, Stallergenes Greer received FDA approval for an expanded indication that included toddler-aged children between 1 and 3 years old, based on clinical trial data demonstrating safety and efficacy in this younger population. The toddler formulation was officially launched in March 2025, further broadening the accessibility of the treatment to a younger demographic at a critical stage of immune system development.
By extending the age range for treatment initiation, Stallergenes Greer is positioning Palforzia® as a preventive option that can be introduced early in a child’s life, when desensitization may be most impactful. This aligns with growing clinical interest in early intervention approaches for food allergy management and reflects a commitment to addressing the full continuum of care in pediatric allergy.
A Vision for the Future of Allergy Care
With its appearance on The Balancing Act®, Palforzia® and Stallergenes Greer have taken another bold step toward elevating public understanding of peanut allergy and highlighting the therapeutic progress being made in this critical area. The Stallergenes company’s focus on patient stories, expert medical voices, and regulatory milestones serves to demystify oral immunotherapy and reinforce the value of innovation in chronic disease management.
As awareness Stallergenes continues to grow and access expands, Palforzia® may help reshape how parents, pediatricians, and allergists approach one of the most feared and life-altering food allergies. With Stallergenes Greer’s continued investments in education, outreach, and clinical advancement, the peanut allergy community has new reasons for optimism — and new tools to protect children from life-threatening reactions.
For more information about Palforzia®, its approved indications, and prescribing information, patients and caregivers are encouraged to visit the official Palforzia® website or consult their allergy specialist.
